Press releaseGlobe Newswire
BriaCell Therapeutics
BCTXZ · NASDAQ
$0.1402+$0.0002 (+0.14%)TodayMarket closed ·
No price history for this range.
Latest news
- Press releaseGlobe Newswire
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
- Press releaseGlobe Newswire
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
- Press releaseGlobe Newswire
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
- Press releaseGlobe Newswire
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
- Press releaseGlobe Newswire
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
- Press releaseGlobe Newswire
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
- Press releaseGlobe Newswire
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
- Press releaseGlobe Newswire
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
- Press releaseGlobe Newswire
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
- Press releaseGlobe Newswire
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
- Press releaseGlobe Newswire
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
- Press releaseGlobe Newswire
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
- Press releaseGlobe Newswire
BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
- Press releaseGlobe Newswire
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.